stockrow
Friday 6 November 2026
Export BLLN’s income statement to Excel — free account
BillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.
- Revenue
- +47.2%
- EPS
- +164.3%
- Free cash flow
- +9.25%
- Total debt
- +60.6%
Quarter to September 2026, against a year earlier
111.16
1.23
−1.09%
Follow BLLN
Alert me
BillionToOne, Inc. (BLLN) Operating margin
BillionToOne, Inc.'s operating margin over the twelve months to 30 September 2026 was 10.2%, up 5.0 percentage points from fiscal 2025 (5.25%). That is above the Diagnostics & Research industry median of −5.68% and above the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | 5.25% | 36.15 |
| FY2024 | −30.9% | 65.99 |
| FY2023 | −96.9% | — |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Sep 2026 | 8.96% | 3.93 |
| Jun 2026 | 5.03% | (11.42) |
| Mar 2026 | 16.5% | 5.69 |
| Dec 2025 | 10.8% | (0.77) |
| 4 more quarters | Free account |
Operating margin against peers
| Company | Operating margin |
|---|---|
| SHC Sotera Health Company compare | 32.7% |
| CDNA CareDx, Inc. compare | 23.4% |
| QGEN QIAGEN N.V. compare | 21.2% |
| VCYT Veracyte, Inc. compare | 17.1% |
| BLLN BillionToOne, Inc. | 10.2% |
| RDNT RadNet, Inc. compare | 3.12% |
| NEO NeoGenomics, Inc. compare | −6.27% |
| ADPT Adaptive Biotechnologies Corporation compare | −16.2% |
| GRAL GRAIL, Inc. compare | −347.3% |
| Diagnostics & Research industry median | −5.68% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on BLLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement